ENSPRYNG DIN 02499681
Health Canada record
| Active ingredient(s) | SATRALIZUMAB 120 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | L04AC19 SATRALIZUMAB |
| Original market date | 26-Aug-2020 |
| Current status date | 26-Aug-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23701 | 2020-06-01 | New Drug Submission (NDS) |